HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional) | RFA DA 22 047

Opportunity Information: Apply for RFA DA 22 047

The HEAL Initiative funding opportunity "Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)" (RFA-DA-22-047) is a discretionary NIH grant designed to support full-scale, R01-level research projects focused on polysubstance use and how health and social service systems respond to it. The overall aim is to generate practical, evidence-based knowledge that helps the field better understand why polysubstance use happens, how it changes over time, and how treatment and service delivery can be improved for people who use multiple substances and have one or more substance use disorders. While clinical trials are allowed, they are optional, meaning applicants can propose either observational, systems, policy, service, or intervention research depending on what best fits their research questions.

The announcement highlights three connected research priorities. First, it seeks studies that expand understanding of the dynamics of polysubstance use. This includes research on patterns of co-use (for example, opioids with stimulants, alcohol with sedatives, or combinations involving cannabis, nicotine, or emerging substances), trajectories over time, risk and protective factors, and contextual drivers such as social environment, drug supply changes, pain management practices, mental health comorbidity, or economic and geographic conditions. The emphasis is on capturing how real-world polysubstance use actually occurs, rather than studying substances in isolation, and on producing insights that can inform prevention, harm reduction, and clinical decision-making.

Second, the opportunity calls for research that examines service provision in the context of polysubstance use, with explicit attention to how existing policies and services shape treatment access, quality, and outcomes. This can include evaluations of how programs screen for and document multiple substance use, how treatment plans address co-occurring substance use disorders, and how care models handle complex presentations such as concurrent stimulant and opioid use. It also encourages work that studies the downstream effects of policy and system design, such as insurance coverage rules, program eligibility criteria, criminal justice practices, prescribing and dispensing regulations, and coordination across sectors like behavioral health, primary care, emergency care, housing services, and peer support. The goal is to identify what helps or hinders successful treatment engagement and recovery when multiple substances are involved.

Third, NIH is looking for studies that develop or test personalized treatment and service approaches tailored to polysubstance use. This priority reflects the reality that people who use multiple substances often have heterogeneous needs, varying risk profiles, different motivations for use, and different responses to standard treatments. Projects may focus on matching individuals to the right mix of medications, behavioral interventions, recovery supports, and wraparound services, or on adapting existing evidence-based treatments so they work better when multiple substances are in play. Personalization can also involve considering co-occurring mental health conditions, chronic pain, infectious disease risks, housing instability, or other factors that can influence adherence and outcomes.

From an administrative standpoint, this is a grant mechanism under NIH with an R01 scope and an indicated award ceiling of $500,000. The opportunity is associated with CFDA numbers 93.213, 93.279, 93.846, and 93.866, and the issuing agency is the National Institutes of Health. The original closing date listed for this specific announcement was March 10, 2022, which is important for applicants to note because it suggests the posted version is tied to a particular receipt cycle and may now be archived; in practice, applicants should confirm whether the opportunity has a current reissue or successor announcement if they are planning to apply.

Eligibility is broad and includes many types of U.S.-based organizations and governments. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and tribal entities, including federally recognized Native American tribal governments and tribal organizations other than federally recognized governments. The announcement also explicitly calls out additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

At the same time, the FOA is clear about restrictions related to foreign involvement. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. In addition, foreign components, as NIH defines them in the NIH Grants Policy Statement, are not allowed under this announcement. In practical terms, the project leadership and performance sites need to be structured to comply with these limitations, with the work being carried out through eligible U.S.-based applicant organizations and allowable domestic components.

Taken together, this opportunity is aimed at advancing the evidence base for addressing polysubstance use in ways that reflect current drug use realities, improve how services are organized and delivered, and support more tailored, person-centered responses that can improve engagement and outcomes for people with complex substance use profiles.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.279, 93.846, 93.866.
• This funding opportunity was created on 2021-12-29.
• Applicants must submit their applications by 2022-03-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 22 047

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: